TGEN Tecogen Inc

Targeted Genetics to Present at Roth Capital Partners New York Conference SEATTLE, Sept. 8 /PRNewswire-FirstCall/ -- H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics Corporation (NASDAQ:TGEN), will speak at the Roth Capital Partners New York conference on Tuesday, September 14, 2004. Ms. Parker will provide a corporate overview, along with highlights from the Company's AIDS vaccine, cystic fibrosis and arthritis programs. Presentation details are as follows: What: Roth Capital Partners New York Conference Where: New York, NY The St. Regis When: Tuesday, September 14, 2004 9:30 AM EDT A live and archived version of Ms. Parker's presentation will be available at http://www.targetedgenetics.com/. About Targeted Genetics Targeted Genetics Corporation develops gene-based products for preventing and treating acquired and inherited diseases. The Company has three clinical product development programs, targeting cystic fibrosis, AIDS prophylaxis and rheumatoid arthritis. The Company also has a promising pipeline of product candidates focused on hemophilia and cancer and a broad platform of gene delivery technologies. For more information about Targeted Genetics visit its website at http://www.targetedgenetics.com/. NOTE: This release contains forward-looking statements regarding our product pipeline and clinical trials. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements. Actual results could differ materially from expectations for a number of reasons, including our failure to make progress with our clinical trials, our failure to obtain positive results from our preclinical programs, our failure to obtain regulatory approval and the other risks described in the section entitled "Factors Affecting Our Operating Results, Our Business and Our Stock Price" in our report on Form 10-Q for the quarter ended June 30, 2004. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. We undertake no duty to publicly announce or report revisions to these statements as new information becomes available that may change our expectations. DATASOURCE: Targeted Genetics Corporation CONTACT: Courtney Self of Targeted Genetics Corporation, +1-206-521-7392 Web site: http://www.targetedgenetics.com/

Copyright